Penny Stock Alert: Novo Energies Corp. NVNC

buy penny stocks, penny stocks, penny stock alerts, hot penny stocks, hottest penny stocks, best penny stocks

Buyer Beware!

Novo Energies Corp. (OTCBB: NVNC) today announced that it has signed an exclusive License Agreement with Immunovative Therapies, Ltd., an Israeli biopharmaceutical company, developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer.

Immunovative has 10 U.S. patents granted, 15 U.S. patents pending and 26 corresponding applications pending internationally and has in-licensed a patent from the University of Arizona related to an individualized cancer vaccine using Chaperone Enriched Cell Lysate (CRCL).

Immunovative has two experimental immunotherapy products for the treatment of cancer in clinical development: AlloStim™ and AlloVax™ covered by these patents and patent applications.

Under the terms of the License Agreement, Novo has been granted an exclusive, worldwide license to commercialize any products covered under Immunovative’s current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. The license also includes the right to charge fees for sublicensing to third parties by indication and territory.

To fully understand the potential of the treatments NVNC now holds exclusive license to, take a moment to read a testimonial from one of the participants in an AlloStim (a tumor-killing treatment developed by Immunovative) clinical trial:

“Between 2006 and 2009 I spent >100 days hospitalized due to side-effects of cancer and the various conventional drugs used to treat my metastatic breast cancer. Those years are mostly dazed and painful memories. During those years I suffered through multiple pathological fractures, was temporarily paralyzed, and had multiple surgeries and multiple rounds of radiation.

The side-effects of the cocktail of conventional drugs I was prescribed included: two weeks of coma-like impairment I don’t remember that terrified my family, other milder chemo-brain memory problems, profound nausea, constipation, infections, weakness, painful drug induced bone infarctions, baldness, skin/mouth/vaginal/other digestive problems and more. After multiple lines of chemo leading up to mid-2009, I was diagnosed to be chemo refractory, with dozens of tumours, in my abdomen and bones. When my husband found the AlloStim trial in 2009 it was thought that I had months to live.

I started in the AlloStim trial 25+ months ago in fall of 2009. AlloStim seems to have transformed my cancer into a condition that I hope to live with for many seasons to come. I travel to get treatments of AlloStim every few months. The treatments are quick and easy when I get there, and the side effects are trivial.

Since 2009 my life now is closer to the quality I had before metastatic cancer. I have been able to return to some of the work I used to do, travel to many places, go on periodic scuba trips, help my kids get settled, and dance at weddings.”

“Licensing this important asset is consistent with Novo’s strategy to transform the Company into a leader in the cancer therapy area,” stated Antonio Treminio, President and Chief Executive Officer of Novo. “We are encouraged to have secured a high-quality, late-stage asset from a world-class partner. Immunovative’s Product Candidates have significant potential not only to be a financial success, but also to make a significant difference in the lives’ of cancer patients with unmet medical needs. We look forward to collaborating with Immunovative to advance the technology and assist in bringing these important Product Candidates to the market.”

Keep an eye on NVNC and watch for more news and updates on this incredible treatment technology and their commercialization strategies coming very soon!

Like Us On Facebook

Interested to find out more on the 2012 Facebook IPO?

Like us at http://www. Facebook.com/AimHighProfits for continuing coverage up to the Facebook IPO launch date.
*****************************************************************************

Would you like to receive the #1 rated penny stock newsletter?

If you answered yes, then receiving Aim High Profits’ Penny Stock Alerts will help guide you to some of the biggest and most profitable trading alerts and techniques that are proven to bring in the “big bucks“.
Visit http://www.AimHighProfits.com to find out more. Alternatively, click here to get more Penny Stock News. You just have to do your due diligence to stay away from all the scams out there these days!

***Reminder: never chase stocks that gap at the open and always protect your profits!

AND AS ALWAYS…………..

  • Do your own research.
  • Trade Responsibly.
  • Verify everything.
  • Move Fast or Get Left Behind.
  • Do not use market orders to enter a position, use limit orders.
  • Have a System That fits You.
  • If a Stock Gaps Open, Look for Pullbacks to Enter.
  • Plan a Trade and Trade a Plan.
  • Always use stop loss orders to protect yourself.
  • Positive Self- Belief.
  • Keep trading as Part of a Balanced life.
  • If a stock breaks below our alert price GET OUT. Do not wait.
  • View Trading as a Score in Points and Not In Money:
  • Always take your profits whenever you can. Do Not Be Greedy.
  • Work Hard at Learning How to Trade Properly and Keep Working.
  • Do something to make someone else’s life better today.

Good luck in making the Best Penny Stock picks.

2012 – Become a Millionaire!!

Advertisements

Got Something to Say or Add......

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s